EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says
独家报道：“如果ED疗法能够场外交易，处方勃起功能障碍市场可能增长三倍，”Petros Pharma总裁表示。
Petros Pharmaceuticals Inc (NASDAQ:PTPI) is a pharmaceutical company focusing on men's health therapeutics.
Petros Pharmaceuticals股份有限公司（纳斯达克：PTPI）是一家以男性健康治疗为重点的药品公司。
In an interview with Benzinga, Fady Boctor, the President and Chief Commercial Officer of Petros Pharmaceuticals, said the company aims to expand access of key prescription pharmaceuticals as over-the-counter (OTC) treatment options.
在接受本新闻的采访时，Petros Pharmaceuticals总裁兼首席商业官Fady Boctor表示，该公司旨在将主要处方药物作为场外交易（OTC）治疗期权扩大使用范围。
Boctor added that Petros is a pure play in the Rx-to-OTC self-care market, focused on bringing its current lead erectile dysfunction (ED) therapeutic OTC while developing a pathway that would take future therapeutics OTC as well.
Boctor补充说，Petros是Rx-to-OTC自我保健市场的纯玩家，专注于将其当前的领先勃起功能障碍（ED）治疗作为OTC药物，并开发一条可以使未来治疗药物也成为OTC的路径。
"Rx-to-OTC is emerging as a substantial self-care industry among...
“Rx-to-OTC正在...
登录免费看全文
登录/注册